Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

Bibliography

• Hosea NA, Collard WT, Cole S, Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009;49:513-33
   PubMed Web of Science ®Google Scholar
• Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007;3:641-65
   PubMed Web of Science ®Google Scholar
• Yengi LG, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharm Res 2007;24:842-58
   PubMed Web of Science ®Google Scholar
• Beaumont K, Smith DA. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 2009;12:61-71
   PubMed Web of Science ®Google Scholar
• Varma MV, Feng B, Obach RS, Physicochemical determinants of human renal clearance. J Med Chem 2009;52:4844-52
   PubMed Web of Science ®Google Scholar
• Bonate PL, Reith K, Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet 1998;34:375-404
   PubMed Web of Science ®Google Scholar
• Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 2003;42:1193-211
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-73
   PubMed Web of Science ®Google Scholar
• Lave T, Chapman K, Goldsmith P, Rowland M. Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 2009;5:1039-48
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157:907-21
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 2009;24:37-52
   PubMed Web of Science ®Google Scholar
• Sahi J. Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Expert Opin Drug Metab Toxicol 2005;1:409-27
   PubMedGoogle Scholar
• Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007;8:341-63
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005;45:689-723
   PubMed Web of Science ®Google Scholar
• Doddareddy MR, Cho YS, Koh HY, In silico renal clearance model using classical Volsurf approach. J Chem Inf Model 2006;46:1312-20
   PubMed Web of Science ®Google Scholar
• Fagerholm U. Prediction of human pharmacokinetics – renal metabolic and excretion clearance. J Pharm Pharmacol 2007;59:1463-71
   PubMed Web of Science ®Google Scholar
• Sun H, Lynda Frassetto, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1-11
   PubMed Web of Science ®Google Scholar
• Jappar D, Hu Y, Keep RF, Smith DE. Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters. Pharm Res 2009;26:172-81
   PubMed Web of Science ®Google Scholar
• Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 2001;1:277-351
   PubMedGoogle Scholar
• Veber DF, Johnson SR, Cheng HY, Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
   PubMed Web of Science ®Google Scholar
• Bednarczyk D, Ekins S, Wikel JH, Wright SH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 2003;63:489-98
   PubMed Web of Science ®Google Scholar
• Ullrich KJ. Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol 1997;158:95-107
   PubMed Web of Science ®Google Scholar
• Ahlin G, Karlsson J, Pedersen JM, Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008;51:5932-42
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001;31:469-97
   PubMed Web of Science ®Google Scholar
• Inotsume N, Nishimura M, Nakano M, The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol 1990;30:50-6
   PubMed Web of Science ®Google Scholar
• Bendayan R, Sullivan JT, Shaw C, Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol 1990;38:165-9
   PubMed Web of Science ®Google Scholar
• Kirch W, Rose I, Demers HG, Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987;13:110-7
   PubMed Web of Science ®Google Scholar
• Somogyi A, Stockley C, Keal J, Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51
   PubMed Web of Science ®Google Scholar
• Takeda M, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 2002;438:137-42
   PubMed Web of Science ®Google Scholar
• Manga N DJ, Rowe PH, Cromin MTD. A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Comb Sci 2003;22:263-73
   Google Scholar
• In: Hardman JG, Gilman AG, Limbird LE, editors, Goodman and Gilman's The Pharmacological Basis Of Therapeutics. McGraw-Hill, New York, USA; 1996
   Google Scholar
• Cruciani G PM, Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000;11:S29-39
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
   PubMed Web of Science ®Google Scholar
• Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58:944-58
   PubMed Web of Science ®Google Scholar
• van Montfoort JE, Hagenbuch B, Groothuis GM, Drug uptake systems in liver and kidney. Curr Drug Metab 2003;4:185-211
   PubMed Web of Science ®Google Scholar
• Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. J Membr Biol 1999;167:103-17
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Fukushima JI, Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001;59:1277-86
   PubMed Web of Science ®Google Scholar
• Lecureur V, Sun D, Hargrove P, Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 2000;57(1):24-35
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Neway WE, Ohe T, In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol 2001;296(3):723-35
   Google Scholar
• Masuda S, Terada T, Yonezawa A, Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-35
   PubMed Web of Science ®Google Scholar
• Otsuka M, Matsumoto T, Morimoto R, A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102:17923-8
   PubMed Web of Science ®Google Scholar
• Tanihara Y, Masuda S, Sato T, Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem Pharmacol 2007;74:359-71
   PubMed Web of Science ®Google Scholar
• Brown G. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993;24:289-300
   PubMed Web of Science ®Google Scholar
• Bourke RS, Chheda G, Bremer A, Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975;35:110-16
   PubMed Web of Science ®Google Scholar
• Masereeuw R, Russel FG. Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 2001;33:299-351
   PubMed Web of Science ®Google Scholar
• Sirtori CR FG, Galli-Kienle M, Cighetti G, Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93
   PubMed Web of Science ®Google Scholar
• Takeda M, Tojo A, Sekine T, Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int 1999;56:2128-36
   PubMed Web of Science ®Google Scholar
• Uwai Y, Ida H, Tsuji Y, Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007;24:811-5
   PubMed Web of Science ®Google Scholar
• Gekle M, Silbernagl S. The role of the proximal tubule in ochratoxin A nephrotoxicity in vivo: toxodynamic and toxokinetic aspects. Renal Physiol Biochem 1994;17:40-9
   PubMedGoogle Scholar
• Yonezawa A, Masuda S, Yokoo S, Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86
   PubMed Web of Science ®Google Scholar
• Yokoo S, Yonezawa A, Masuda S, Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87
   PubMed Web of Science ®Google Scholar
• Feng B, Obach RS, Burstein AH, Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 2008;83:567-76
   PubMed Web of Science ®Google Scholar
• USRDS. 2009 Atlas of CKD and ESRD. United States Renal Data System; 2009
   Google Scholar
• Cheng Q, Aleksunes LM, Manautou JE, Drug-metabolizing enzymes and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 2008;5:77-91
   PubMed Web of Science ®Google Scholar
• Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 2002;62:514-24
   PubMed Web of Science ®Google Scholar
• Nowicki MT, Aleksunes LM, Sawant SP, Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2008;2:11-7
   PubMedGoogle Scholar
• Laouari D, Yang R, Veau C, Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol 2001;280:F636-45
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Motohashi H, Ueo H, Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res 2004;21:61-7
   PubMed Web of Science ®Google Scholar
• Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1-11
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and disposition. Semin Dial 2003;16:45-50
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4:1065-74
   PubMed Web of Science ®Google Scholar
• Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:898-903
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Abraham S, Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009;85:305-11
   PubMed Web of Science ®Google Scholar
• Bianchetti G, Graziani G, Brancaccio D, Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976;1:373-84
   PubMedGoogle Scholar
• Giacomini KM, Gibson TP, Levy G. Plasma protein binding of d-propoxyphene in normal subjects and anephric patients. J Clin Pharmacol 1978;18:106-9
   PubMed Web of Science ®Google Scholar
• Kanfer A, Stamatakis G, Torlotin JC, Changes in erythromycin pharmacokinetics induced by renal failure. Clin Nephrol 1987;27:147-50
   PubMed Web of Science ®Google Scholar
• De Martin S, Orlando R, Bertoli M, Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther 2006;80:597-606
   PubMed Web of Science ®Google Scholar
• Singlas E, Pioger JC, Taburet AM, Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989;46:190-7
   PubMed Web of Science ®Google Scholar
• Kim YG, Shin JG, Shin SG, Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 1993;54:612-20
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5
   PubMed Web of Science ®Google Scholar